Immune Checkpoint Inhibitors and Mismatch Repair Status in Advanced Endometrial Cancer: Elective Affinities
Alessandro Rizzo
Abstract
Since endometrial cancers (ECs) are frequently TMB-H and MSI-H/dMMR tumors, this element has provided the rationale for testing immune checkpoint inhibitors (ICIs), which have recently emerged as a potential game-changer. However, several questions remain to be addressed, including the identification of patients who may benefit from the addition of ICIs as well as those who do not need immunotherapy. In the current paper, we provide an overview of the clinical development of immunotherapy in advanced or recurrent EC, discussing the role of MMR and the "elective affinities" between ICIs and this predictive biomarker in this setting.
Topics & Concepts
MedicineEndometrial cancerImmunotherapyBiomarkerOncologyImmune checkpointInternal medicineCancerChemistryBiochemistryEndometrial and Cervical Cancer TreatmentsCancer Immunotherapy and BiomarkersOvarian cancer diagnosis and treatment